CLVLF (Clinuvel Pharmaceuticals) Current Deferred Revenue: $0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CLVLF Clinuvel Pharmaceuticals Ltd CLVLF
92 GF Score
Price $6.37
GF Value $11.76
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Clinuvel Pharmaceuticals Current Deferred Revenue?

Clinuvel Pharmaceuticals CLVLF 92 Current Deferred Revenue is $0.00 Mil as of Dec. 2025. GuruFocus rates CLVLF with a GF Score™ of 92/100 and a GF Value™ of $11.76 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Clinuvel Pharmaceuticals's current deferred revenue for the quarter that ended in Dec. 2025 was $0.00 Mil.

Clinuvel Pharmaceuticals Current Deferred Revenue Related Terms

Clinuvel Pharmaceuticals Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Clinuvel Pharmaceuticals's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Clinuvel Pharmaceuticals Current Deferred Revenue Chart

Clinuvel Pharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Clinuvel Pharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CLVLF
92GF Score
Clinuvel Pharmaceuticals Ltd CLVLF
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of $0.00 Mil mean?
Clinuvel Pharmaceuticals (CLVLF) has a Current Deferred Revenue of $0.00 Mil as of Dec. 2025. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Clinuvel Pharmaceuticals and its competitors.
Is Clinuvel Pharmaceuticals' Current Deferred Revenue too high?
Clinuvel Pharmaceuticals' current Current Deferred Revenue is $0.00 Mil. Overall, Clinuvel Pharmaceuticals has a GF Score™ of 92/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Clinuvel Pharmaceuticals' Current Deferred Revenue compare to VRTX and REGN?
Clinuvel Pharmaceuticals' Current Deferred Revenue of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Biotechnology company?
A good Current Deferred Revenue depends on the Biotechnology industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Clinuvel Pharmaceuticals and its competitors. Clinuvel Pharmaceuticals's current Current Deferred Revenue is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clinuvel Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Clinuvel Pharmaceuticals (CLVLF) is currently considered Significantly Undervalued. The stock's GF Value™ is $11.76, compared to a current price of $6.37 — trading 45.8% below its estimated fair value. The current Current Deferred Revenue is $0.00 Mil. Clinuvel Pharmaceuticals' overall GF Score™ is 92/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Clinuvel Pharmaceuticals (CLVLF), the current Current Deferred Revenue is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Clinuvel Pharmaceuticals (CLVLF) Overvalued in 2026?

Based on GuruFocus' analysis, Clinuvel Pharmaceuticals stock appears to be undervalued. The current stock price of $6.37 is trading 45.8% below its estimated GF Value™ of $11.76. GuruFocus considers Clinuvel Pharmaceuticals to be Significantly Undervalued.

Key valuation signals for CLVLF:

  • Current Deferred Revenue: $0.00 Mil
  • GF Value™: $11.76 vs. price of $6.37 (45.8% below fair value)
  • GF Score™: 92/100 with 2 warning signs

No single metric tells the full story. See the CLVLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Clinuvel Pharmaceuticals Business Description

Address 535 Bourke Street, Level 22, Melbourne, VIC, AUS, 3000
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.
92GF Score

Get the complete analysis for CLVLF

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.37
Price
$11.76
GF Value